DrugPatentWatch Database Preview

Details for Patent: 6,573,293

« Back to Dashboard

Which drugs does patent 6,573,293 protect, and when does it expire?

Patent 6,573,293 protects SUTENT and is included in one NDA.

This patent has fifty-five patent family members in thirty-nine countries.

Summary for Patent: 6,573,293

Title:	Pyrrole substituted 2-indolinone protein kinase inhibitors
Abstract:	The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
Inventor(s):	Tang; Peng Cho (Moraga, CA), Miller; Todd A. (Bend, OR), Li; Xiaoyuan (Los Altos, CA), Sun; Li (Foster City, CA), Wei; Chung Chen (Foster City, CA), Shirazian; Shahrzad (Corte Madera, CA), Liang; Congxin (Sunnyvale, CA), Vojkovsky; Tomas (San Francisco, CA), Nematalla; Asaad S. (Concord, CA), Hawley; Michael (Kalamazoo, MI)
Assignee:	Sugen, Inc. (South San Francisco, CA) Pharmacia & Upjohn Co. (Kalamazoo, MI)
Application Number:	09/783,264
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,573,293
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 6,573,293

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Cppi Cv	SUTENT	sunitinib malate	CAPSULE;ORAL	021938-001	Jan 26, 2006		RX	Yes	No			Y	Y		TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
Cppi Cv	SUTENT	sunitinib malate	CAPSULE;ORAL	021938-001	Jan 26, 2006		RX	Yes	No			Y	Y		ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
Cppi Cv	SUTENT	sunitinib malate	CAPSULE;ORAL	021938-002	Jan 26, 2006		RX	Yes	No			Y	Y		TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
Cppi Cv	SUTENT	sunitinib malate	CAPSULE;ORAL	021938-002	Jan 26, 2006		RX	Yes	No			Y	Y		ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY

Non-Orange Book US Patents Family Members for Patent 6,573,293

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,125,905	Pyrrole substituted 2-indolinone protein kinase inhibitors
7,572,924	Pyrrole substituted 2-indolinone protein kinase inhibitors

International Family Members for US Patent 6,573,293

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Czech Republic	303705
Germany	60129794
Argentina	034118
Austria	369359